Article Text

Download PDFPDF

CPC-091 Natalizumab in Cypriot Patients with Relapsing Remitting Multiple Sclerosis: Three Year Data on Safety, Efficacy and Frequency of Anti-JC Virus Antibodies
  1. E Kkolou,
  2. E Gaglia,
  3. J Toufexis,
  4. M Pantzaris
  1. The Cyprus Institute of Neurology and Genetics, Clinical Neurosciences, Nicosia, Cyprus


Background Natalizumab (NAT) is a recombinant humanised anti-α4-integrin antibody used in treating Relapsing Remitting (RR) Multiple Sclerosis (MS).

Purpose To evaluate the long-term safety and efficacy of NAT in Cypriot patients, to assess the frequency of anti-JC Virus (JCV) antibodies and implement a strategy for the prevention of PML.

Materials and Methods Twenty-two patients were studied prospectively for 3 years.

The patients received 300 mg of NAT intravenously every 4 weeks. MRI examinations were performed at study entry and 12–24 months after the start of treatment. JCV antibody testing was performed after two years of treatment.

Results Six patients (27.3%) discontinued the study due to: Severe allergic reaction (9%), generalised atony, fatigue and weakness (4%), recurring herpes infection (4%), family planning (4%) and presence of anti-JCV antibodies (anti-JCV positive) due to previous immunosuppressive therapy (4%).

Most frequently reported side effects were: cardiovascular (41%), general (41%), laboratory abnormalities (41%), gastrointestinal (23%), neurological (18%), allergic reactions (18%) and depression (14%).

After three years of NAT treatment, a 55.2% decrease from the baseline mean annual relapse rate was observed, as well as improvement of 0.3 points on the mean Expanded Disability Status Scale (EDSS) Score.

87.5% of the patients completing the study had repeat MRI scans. Of those, 85.7% were found to have no new or gadolinium-enhancing lesions.

JC Virus antibody testing was performed after two years of NAT. Of the thirteen samples, eight (61.5%) tested positive. Two of those (25%) discontinued NAT due to previous IV mitoxantrone treatment. The remaining patients continued treatment under close supervision by the attending neurologist.

No cases of Progressive Multifocal Leukoencephalopathy were reported.

Conclusions Long-term therapy with natalizumab proved to be safe and effective in our population. Strict follow-up criteria were implemented for JCV antibody-positive patients remaining on treatment with natalizumab for more than two years.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.